Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal
This article was originally published in The Pink Sheet Daily
Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.
You may also be interested in...
Weeks after immuno-oncology tie-up with Sanofi, Evotec signs a collaboration in fibrotic disease with Pfizer. Epirus expands its biosimilars capabilities with the acquisition of Dutch biotech Bioceros.
AstraZeneca and Genentech sign agreements with a number of firms with promising early stage assets, with Bristol looking to spread reach into rare cancers; J&J joins the game. Drama continues to unfold for Mylan/Perrigo, Shire/Baxalta and Horizon/Depomed.
After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.